FDA opts to nail down REMS plan for Sage's landmark postpartum depression drug, delays final decision
A month before the FDA is scheduled to hand down what many expect to be an OK for Sage Therapeutics’ landmark drug for postpartum depression …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
